Method for measuring sialic acid lewis antigen, reagent for measurement, and kit for measurement
By using latex particles of 200 nm to 400 nm and ultrasonic treatment technology in the sialic acid Lewis antigen assay, the problems of insufficient sensitivity and non-specific reactions in the prior art were solved, and a high sensitivity and accuracy of sialic acid Lewis antigen assay was achieved.
Patent Information
- Application Number
- CN202380030311.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-29
- Filing Date
- 2023-03-23
- Publication Date
- 2024-11-19
AI Technical Summary
The existing sialic acid-Lewis antigen assay methods have insufficient sensitivity and non-specific reaction problems, making it difficult to accurately determine high-sensitivity sialic acid-Lewis antigen.
Using latex condensation immunoassay method with an average particle size of 200 nm to 400 nm, latex particles combined with antibodies or antigen-binding fragments that recognize sialic acid Lewis antigen react with the sample, and ultrasonic treatment is performed in an aqueous medium to improve the measurement accuracy. .
A high sensitivity sialic acid Lewis antigen assay was achieved, reducing non-specific reactions and improving the accuracy of the determination results.
Smart Images

Figure BDA0005059319210000081 
Figure BDA0005059319210000311 
Figure BDA0005059319210000321
Abstract
Description
Technical Field
[0001] The present invention relates to a method for determining sialyl Lewis antigen, a reagent for determination and a kit for determination. Background Art
[0002] In recent years, many antibodies against the sugar chain antigen sialyl Lewis antigen used as a cancer marker have been reported. Among them, the monoclonal antibody DUPAN-2 was reported to be a monoclonal antibody produced using human pancreatic cancer cultured cells HPAF as an immunogen, and it reacts with a mucin-like protein (antigen) efficiently produced from pancreatic cancer cells (Non-patent Documents 1, 2). This antigen is called DUPAN-2 antigen and is used as a cancer marker for pancreatic cancer, cholangiocarcinoma, etc.
[0003] As a method for measuring DUPAN-2 antigen, competition radioimmunoassay (Non-Patent Document 1) and enzyme-linked immunosorbent assay (Enzyme-Linked ImmunoSorbent Assay) (Patent Document 1) have been reported.
[0004] The aforementioned measurement methods use a labeling method based on the following principle: the DUPAN-2 antigen in the sample and the antibody that binds to the DUPAN-2 antigen undergo an antigen-antibody reaction to form an immune complex, and then the amount of the label in the immune complex is measured to measure the DUPAN-2 antigen. However, these labeling methods generally require washing (B / F separation) with a washing solution to remove substances other than the DUPAN-2 antigen contained in the sample before measuring the amount of the label in the immune complex, and the measurement takes time.
[0005] On the other hand, one of the immunoassays that does not use labels is the latex agglutination immunoassay method (Patent Documents 2, 3). The latex agglutination immunoassay method is the following method: using an antibody bound to a component to be measured or latex particles bound to an antigen, an antigen-antibody reaction occurs with the component to be measured in the sample, and the turbidity change caused by the aggregation of the latex particles is measured by absorbance; since it is a method that does not require B / F separation, it is also suitable for measurements using a general automatic analyzer for biochemical tests. However, the latex agglutination immunoassay method has the problem of poor measurement sensitivity, and is difficult to apply to the measurement of components to be measured that require high sensitivity. In addition, the latex agglutination immunoassay method does not include a B / F separation step, so it is easily affected by nonspecific reactions caused by inclusions contained in the sample, and there is also a problem of difficulty in accurate measurement.
[0006] Prior art literature
[0007] Patent Literature
[0008] Patent Document 1: International Publication No. 2019 / 189874
[0009] Patent Document 2: Japanese Patent Application Publication No. 2006-017745
[0010] Patent Document 3: Japanese Patent Application Publication No. 2014-153102
[0011] Non-patent literature
[0012] Non-patent document 1: Metzgar et al., “Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma”, Proceedings of the National Academy of Sciences of the United States of America, 1984, Vol. 81, pp. 5242-5246
[0013] Non-patent document 2: Sakurabayashi, "Cancer-related glycoprotein antigen, DU-PAN-2 Kanko Research I. Enzyme immunoassay basics for measurement of normal human body distribution", Clinical Pathology, 1986, Volume 34, pp. 705-710 Summary of the invention
[0014] Problems to be solved by the invention
[0015] Since sialyl Lewis antigen is used as a cancer marker, there is a need for a measurement reagent and a measurement kit capable of performing a measurement with higher sensitivity. An object of the present invention is to provide a method, a measurement reagent and a measurement kit for measuring sialyl Lewis antigen in a sample with high sensitivity.
[0016] Means for solving problems
[0017] The present inventors have conducted intensive studies to solve the above problems and have found that a latex agglutination immunoassay method using latex particles having an average particle size of 200 nm to 400 nm can measure sialyl Lewis antigen with high sensitivity, thereby completing the invention of the present disclosure.
[0018] That is, the present disclosure provides the following in one embodiment.
[0019] [1] A latex agglutination immunoassay method for sialyl Lewis antigen in a sample, wherein the sialyl Lewis antigen in the sample is reacted with latex particles bound with an antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen in an aqueous medium, wherein the average particle size of the latex particles is 200 nm to 400 nm.
[0020] [2] The method according to [1], comprising the step of treating the sample with ultrasound.
[0021] [3] A latex agglutination immunoassay method for determining sialyl Lewis antigen in a sample, comprising:
[0022] (1) a step of mixing a sample containing a sialyl Lewis antigen with an aqueous medium; and
[0023] (2) a step of reacting the sialyl Lewis antigen in the sample with latex particles to which an antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen is bound, in the solution obtained in step (1);
[0024] The average particle size of the latex particles in step (2) is 200 nm to 400 nm.
[0025] [4] The method according to [3], wherein after the step (1) and / or after the step (2), a step of treating the sample with ultrasound is included.
[0026] [5] The method according to [3] or [4], wherein the step (1) and / or the step (2) is performed in the presence of metal ions.
[0027] [6] The method according to [5], wherein the metal ion is a divalent or higher valent metal ion.
[0028] [7] The method according to any one of [1] to [6], wherein the binding between the antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen and the latex particles is chemical binding.
[0029] [8] The method according to any one of [1] to [7], wherein the sialyl Lewis antigen is a DUPAN-2 antigen.
[0030] [9] A reagent for latex agglutination immunoassay of sialyl Lewis antigen in a sample, comprising latex particles to which an antibody recognizing sialyl Lewis antigen or an antigen-binding fragment thereof is bound, wherein the latex particles have an average particle size of 200 nm to 400 nm.
[0031]
[10] The reagent according to [9], wherein the latex agglutination immunoassay includes a step of treating the sample with ultrasonic waves.
[0032]
[11] The reagent according to [9], comprising instructions for treating the sample with ultrasound.
[0033]
[12] The reagent according to [9], which is used in an analysis device equipped with an ultrasonic processing function.
[0034]
[13] The reagent according to any one of [9] to
[12] , comprising a metal ion.
[0035]
[14] The reagent according to
[13] , wherein the metal ion is a divalent or higher valent metal ion.
[0036]
[15] The reagent according to any one of [9] to
[14] , wherein the binding between the antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen and the latex particles is chemical binding.
[0037]
[16] The reagent according to any one of [9] to
[15] , wherein the sialyl Lewis antigen is a DUPAN-2 antigen.
[0038]
[17] A kit for latex agglutination immunoassay of sialyl Lewis antigen in a sample, comprising: a first reagent comprising an aqueous medium; and a second reagent comprising latex particles bound with an antibody recognizing sialyl Lewis antigen or an antigen-binding fragment thereof, wherein the average particle size of the latex particles is 200 nm to 400 nm.
[0039]
[18] The kit according to
[17] , wherein the latex agglutination immunoassay includes a step of treating the sample with ultrasound.
[0040]
[19] The kit according to
[17] , comprising instructions for treating the sample with ultrasound.
[0041]
[20] The kit according to
[17] , which is used in an analysis device equipped with an ultrasonic processing function.
[0042]
[21] The kit according to any one of
[17] to
[20] , wherein the first reagent and / or the second reagent contains a metal ion.
[0043]
[22] The kit according to
[21] , wherein the metal ion is a divalent or higher valent metal ion.
[0044]
[23] The kit according to any one of
[17] to
[22] , wherein the binding between the antibody recognizing the sialyl Lewis antigen or its antigen-binding fragment and the latex particles is chemical binding.
[0045]
[24] The kit according to any one of
[17] to
[23] , wherein the sialyl Lewis antigen is a DUPAN-2 antigen.
[0046] Effects of the Invention
[0047] According to the present disclosure, a method for measuring sialyl Lewis antigen in a sample with high sensitivity, a reagent for measurement, and a kit for measurement can be provided. DETAILED DESCRIPTION
[0048] Hereinafter, the method for implementing the present disclosure will be described in detail. It should be noted that the embodiment described below only shows an example of a representative embodiment of the present disclosure, and the scope of the disclosure should not be interpreted as narrow. In addition, the numerical range represented by "~" represents a range that includes the numerical values recorded before and after "~" as the minimum and maximum values, respectively. In addition, the amount of each component in the solution refers to the total amount of the multiple substances present in the reaction or reagent, unless otherwise specified, when there are multiple substances belonging to each component in the solution.
[0049] In the present disclosure, “% (w / v)” refers to the percentage of mass (g) based on volume (100 mL).
[0050] In the present disclosure, when it is expressed that an antibody "binds" or "reacts" with a sialyl Lewis antigen, or that an antibody "recognizes" a sialyl Lewis antigen, it includes the meanings commonly used in the field of the present disclosure and is used in the same meaning. As a method for confirming that an antibody "binds" with a sialyl Lewis antigen, it can be carried out by methods known to those skilled in the art that utilize the principles of antigen immobilized ELISA, competitive ELISA, sandwich ELISA, surface plasmon resonance, immunochromatography, quartz crystal microbalance, etc.
[0051] "Latex agglutination immunoassay for sialyl Lewis antigen in a sample"
[0052] One embodiment of the latex agglutination immunoassay method for sialyl Lewis antigen in a sample disclosed herein is a method of reacting sialyl Lewis antigen in a sample with latex particles having an average particle size of 200 nm to 400 nm to which an antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen is bound in an aqueous medium.
[0053] "Aqueous medium"
[0054] As the aqueous medium in the determination method disclosed herein, deionized water, distilled water, buffer solution, etc. can be cited, preferably buffer solution. As the buffer used in the preparation of the buffer solution, acetic acid buffer solution, Good buffer solution, etc. can be cited. The buffer solution can be used alone or in combination of two or more.
[0055] The aqueous medium may contain salts, metal ions, sugars, proteins, surfactants, etc. As salts, lithium chloride, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, etc. may be mentioned. As metal ions, sodium ions, magnesium ions, manganese ions, zinc ions, etc. may be mentioned. As sugars, mannitol, sorbitol, etc. may be mentioned. As proteins, bovine serum albumin (hereinafter referred to as BSA), etc. may be mentioned. As surfactants, anionic surfactants, cationic surfactants, zwitterionic surfactants, nonionic surfactants, etc. may be mentioned.
[0056] "Sample"
[0057] The sample used in the measurement method of the present invention is not particularly limited as long as it is a sample that may contain sialyl Lewis antigen, and examples include biological samples selected from any one or more of whole blood, plasma, serum, urine, ascites, cerebrospinal fluid, saliva, amniotic fluid, urine, sweat and pancreatic juice, and preferably whole blood, plasma, serum, ascites, etc.
[0058] The sample in the measurement method disclosed herein may be a cell lysate of a genetically modified microorganism, a genetically modified animal cell or a cultured cancer cell that produces a sialyl Lewis antigen, or may be a culture supernatant obtained when the genetically modified microorganism, the genetically modified animal cell or the cultured cancer cell is cultured.
[0059] Examples of microorganisms include yeast, and examples of animal cells include Chinese hamster ovary cells (CHO cells). Examples of cultured cancer cells include cultured pancreatic cancer cells, cultured colorectal cancer cells, cultured liver cancer cells, cultured bile duct cancer cells, cultured breast cancer cells, and cultured ovarian cancer cells.
[0060] The sample in the assay method disclosed herein may be an aqueous medium containing a sialyl Lewis antigen, for example, a sialyl Lewis antigen diluted with phosphate buffered saline (10 mmol / L phosphate buffer containing 0.15 mol / L sodium chloride, pH 7.2, hereinafter referred to as PBS) etc. The sialyl Lewis antigen contained in the aqueous medium may be the above-mentioned biological sample, the above-mentioned cell lysate, or the sialyl Lewis antigen purified from the above-mentioned culture supernatant, etc.
[0061] "Sialyl Lewis antigen"
[0062] The sialyl Lewis antigen in the determination method disclosed in the present invention is a sugar chain antigen, which is expressed hyperactively in cancer cells as the cells become cancerous. Therefore, the sialyl Lewis antigen is used as a cancer marker. The sialyl Lewis antigen in the present invention refers to a mucin-like protein (glycoprotein), a sialyl Lewis sugar chain or a peptide having the sugar chain to which an antibody that recognizes the sialyl Lewis antigen can bind. As sialyl Lewis antigens, for example, CA-19-9 (sialyl Lewis A antigen), DUPAN-2 antigen (sialyl Lewis C antigen), SLX (sialyl Lewis Xi antigen), CSLEX (sialyl Lewis X antigen), NCC-ST-439 antigen, etc. can be cited, and preferably DUPAN-2 antigen can be cited. There is no particular limitation on the sialyl Lewis antigen, and for example, the sialyl Lewis antigen contained in the serum of a cancer patient or the culture supernatant of a cultured cancer cell can be used.
[0063] "DUPAN-2 Antigen"
[0064] The DUPAN-2 antigen in the measurement method disclosed herein refers to a mucin-like protein (glycoprotein) to which the monoclonal antibody "DUPAN-2" (Metzgar et al., "Antigens of Human Pancreatic Adenocarcinoma Cells Defined by Murine Monoclonal Antibodies", CANCER RESEARCH (1982), 42: 601-608) can bind, a sugar chain to which the monoclonal antibody "DUPAN-2" can bind, or a peptide containing the sugar chain. Specifically, the DUPAN-2 antigen refers to a sialyl Lewis C sugar chain reported to be bindable by the monoclonal antibody "DUPAN-2" (Kawa et al., "Epitope Analysis of Span-1 and DUPAN-2 using Synthesized Glycoconjugates Sialyllact-N-Fucopentaose II and Sialyllact-N-Tetraose", Pancreas (1994), 9 (6): 692-697), a protein having the sugar chain, or a peptide having the sugar chain. As the DUPAN-2 antigen, the DUPAN-2 antigen contained in the ascites of a human pancreatic cancer patient or the culture supernatant of human pancreatic cancer cultured cells HPAF can be used. Human pancreatic cancer cultured cells HPAF can be obtained from ATCC (American Type Culture Collection) under the name of "HPAF-II".
[0065] "Antibodies or antigen-binding fragments thereof that recognize sialyl Lewis antigen"
[0066] In the assay method disclosed herein, the antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen refers to an antibody that can recognize the sialyl Lewis sugar chain of sialyl Lewis antigen and bind to the sialyl Lewis antigen. Since sialyl Lewis antigen is a macromolecule (multivalent antigen) having multiple epitopes, the antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen may be one or two (a first antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen, and a second antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen).
[0067] When there are two antibodies or antigen-binding fragments thereof that recognize sialyl Lewis antigen, the site (epitope) of sialyl Lewis antigen to which the first antibody or antigen-binding fragment thereof and the second antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen bind may be the same or different. In addition, the first antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen and the second antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen may be the same antibody or different antibodies.
[0068] In the assay method disclosed herein, the antibody or antigen-binding fragment thereof that binds to the DUPAN-2 antigen among the antibodies or antigen-binding fragments thereof that recognize the sialyl Lewis antigen may be an antibody or antigen-binding fragment thereof that reacts with the DUPAN-2 antigen having a sugar chain structure of the following chemical formula 1 disclosed in International Publication No. 2019 / 189874 and does not react with the NCC-ST-439 antigen having a sugar chain structure of the following chemical formula 2,
[0069] [Chemical formula 1]
[0070] Neu5Acα2-3Galβ1-3GlcNACβ1-3Gal-
[0071] [Chemical formula 2]
[0072]
[0073] It can be an antibody or an antigen-binding fragment thereof whose reactivity with the above-mentioned NCC-ST-439 antigen is less than 10% of its reactivity with the above-mentioned DUPAN-2 antigen, or it can be an antibody or an antigen-binding fragment thereof whose reactivity with the above-mentioned NCC-ST-439 antigen is less than 1% of its reactivity with the above-mentioned DUPAN-2 antigen. In addition, as a monoclonal antibody that binds to the DUPAN-2 antigen, the aforementioned monoclonal antibody "DUPAN-2" (Metzgar et al., "Antigens of Human Pancreatic Adenocarcinoma Cells Defined by Murine Monoclonal Antibodies", CANCER RESEARCH (1982), 42: 601-608) and the like can be cited. Among them, in the present disclosure, the monoclonal antibody DUPAN-2 is also recorded as "DUPAN-2 antibody".
[0074] The antibody that recognizes sialyl Lewis antigen can be mouse antibody, rat antibody, rabbit antibody, human antibody, humanized antibody or chimeric antibody, or can also be antibody from other species.In addition, the antibody that recognizes sialyl Lewis antigen can be any class (such as IgG, IgE, IgM, IgD and IgA), any subclass (such as IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) of immunoglobulin molecule.
[0075] Examples of antibodies that recognize sialyl Lewis antigen include monoclonal antibodies, polyclonal antibodies, dimers, and multimers. From the viewpoint of homogeneity and stability, monoclonal antibodies are preferred.
[0076] In the assay method disclosed herein, an antigen-binding fragment refers to a part of an antibody that recognizes the above-mentioned sialyl Lewis antigen, and refers to a fragment that contains the variable region of an antibody or at least contains an antigen-binding region. As antigen-binding fragments in the present disclosure, for example, Fab, Fab', F(ab')2, Fv fragments, linear antibodies, single-chain antibodies (scFv), sc(Fv)2, Fab3, region antibodies (dAb), double-chain antibodies (diabody), three-chain antibodies (triabody), four-chain antibodies (tetrabody) and minibodies (minibody) can be cited. "Fv fragment" is the smallest antigen-binding fragment, which contains a complete antigen recognition region and an antigen-binding region.
[0077] The antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen in the assay method disclosed herein can be obtained by using sialyl Lewis antigen or cancer cells that produce sialyl Lewis antigen as an immunogen and utilizing a conventional method for producing antibodies. For example, it can be obtained by producing a cell (hybridoma) obtained by fusing an antibody-producing cell obtained by immunizing an animal with the above-mentioned immunogen with a myeloma cell to obtain a monoclonal antibody produced by the above-mentioned hybridoma.
[0078] "Latex particles"
[0079] The latex agglutination immunoassay method for sialyl Lewis antigen in a sample in the present disclosure can measure sialyl Lewis antigen with high sensitivity by using latex particles having an average particle size (D50) of 200 nm to 400 nm (hereinafter also referred to as "latex particles").
[0080] In the determination method disclosed in the present invention, as latex particles, there is no particular limitation as long as the average particle diameter is 200nm to 400nm, as long as the latex particles can be used for the determination method of sialyl Lewis antigen disclosed in the present invention, or can be used for the determination reagent or determination kit disclosed later. As the average particle diameter of the latex particles, for example, it can be 200nm to 250nm, 250nm to 300nm, 300nm to 350nm, 350nm to 400nm, 200nm to 300nm, 250nm to 350nm, 300nm to 400nm, 200nm to 350nm, 250nm to 400nm. The average particle diameter (D50) can be measured, for example, using a laser diffraction particle size distribution meter. Regarding the average particle diameter (D50), the particle diameter when the cumulative value in the particle size distribution is 50% (volume basis) is taken as the average particle diameter. The shape of the latex particles is not particularly limited, and examples thereof include spherical shapes, elliptical shapes, and concavo-convex shapes.
[0081] As the above-mentioned latex particles, for example, microparticles of organic polymer substances, microparticles of inorganic oxides, microparticles whose surfaces of the above-mentioned microparticles serving as cores are surface-treated with organic substances, etc. ... of the above-mentioned latex particles, particularly preferably, are polystyrene-based synthetic polymers, acrylic acid-based monomers used as components for imparting electric charge, monomers having sulfonic acid, etc., etc., etc., etc., etc., etc., etc., etc., etc., are copolymerized.
[0082] The above-mentioned latex particles are particularly preferably polystyrene latex particles. When using latex with strong hydrophobicity on the surface such as polystyrene latex particles, the adsorption of proteins and peptides can be smooth. In addition, based on the mutual repulsion of negative charges on the surface, the polystyrene latex particles obtained by soap-free polymerization without using a surfactant as an emulsifier can stably exist even without a surfactant, so it is particularly preferred. In addition, various modified latexes (such as carboxylic acid modified latex), magnetic latex (latex containing magnetic particles) etc. can also be used as needed.
[0083] "Latex particles bound to an antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen"
[0084] In the assay method disclosed herein, the latex particles bound with an antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen refer to latex particles to which an antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen (a first antibody or an antibody fragment thereof that recognizes a sialyl Lewis antigen, and a second antibody or an antibody fragment thereof that recognizes a sialyl Lewis antigen) is bound. In other words, the antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen may also be carried on the latex particles.
[0085] As the binding method of the antibody or its antigen-binding fragment that recognizes sialyl Lewis antigen and latex particles, there is no particular limitation as long as it can be used for the determination method of sialyl Lewis antigen disclosed herein or can be used for the determination reagent or determination kit disclosed herein described later, and can include a binding based on physical adsorption, a binding based on chemical binding, etc. As physical adsorption, electrostatic coupling, hydrogen bonding and hydrophobic coupling can be mentioned. As chemical bonding, covalent bonding, coordination bonding, etc. can be mentioned.
[0086] The antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen can be directly bound to the latex particles by the aforementioned physical adsorption and / or chemical binding, or can be indirectly bound to the latex particles. As an indirect binding method, there can be cited a method of binding the antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen to the latex particles by utilizing the specific binding of a group of affinity substances such as biotin and avidins (avidin, streptavidin, neutravidin, etc.); a method of binding to the latex particles by a covalent bond via a linker molecule, etc.
[0087] When a set of affinity substances is used, latex particles to which an antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof is bound can be generated by binding an antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof to which one (A) of the set of affinity substances is bound to latex particles to which another (a) of the set of affinity substances is bound.
[0088] Examples of the combination of Aa include the following combinations.
[0089] Combination of biotin and avidin (avidin, neutravidin, streptavidin, etc.);
[0090] Combination of avidins (avidin, neutravidin, streptavidin, etc.) and biotin;
[0091] A combination of an Fc region of an antibody that recognizes a sialyl Lewis antigen and an antibody that binds to the Fc region.
[0092] Examples of linking molecules include molecules that can covalently bond both the functional groups on the surface of latex particles and the functional groups possessed by the antibody that recognizes sialyl Lewis antigen or its antigen-binding fragment. For example, it is preferred to use a molecule that has both a first reactive group that can react with the functional groups possessed by the antibody that recognizes sialyl Lewis antigen or its antigen-binding fragment and a second reactive group that can react with the functional groups on the surface of latex particles, and the first reactive group and the second reactive group are different groups.
[0093] As the functional groups possessed by the antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen, and the functional groups retained on the surface of the latex particles, there can be mentioned carboxyl, amino, glycidyl, thiol, hydroxyl, amide, imino, N-hydroxysuccinyl, maleimide, etc. As the reactive groups in the linker molecule, there can be mentioned allyl azide, carbodiimide, hydrazide, aldehyde, hydroxymethylphosphine, imide ester, isocyanate, maleimide, N-hydroxysuccinimide ester, pentafluorophenyl (PFP) ester, psoralen, pyridyl disulfide, vinyl sulfone, etc.
[0094] "Latex agglutination immunoassay method"
[0095] In the assay method disclosed herein, the latex agglutination immunoassay method may be a method in which the sialyl Lewis antigen in the sample is reacted with latex particles bound with an antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen in an aqueous medium to form a complex comprising the sialyl Lewis antigen and the latex particles bound with the antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen, and the latex particles are selectively agglutinated. The agglutination may be detected by measuring absorbance or scattered light, etc.
[0096] When the sialyl Lewis antigen and the latex particles are "reacted", for example, the sialyl Lewis antigen and the latex particles may be added to an aqueous medium. Alternatively, the sialyl Lewis antigen and the latex particles may be mixed in an aqueous medium.
[0097] The latex agglutination immunoassay method can be implemented by combining a so-called method using a device for dispensing a solution such as a whole pipette, a thermostatic bath for heating a latex agglutination immunoreaction, an absorbance or scattered light measuring device, etc., or can be implemented using a so-called automatic analyzer that performs a series of solution dispensing, heating, and absorbance or scattered light measurements on the device. The automatic analyzer is not particularly limited, and can be, for example, an automatic analyzer having a mechanism that inserts a rod or spatula-shaped stirring member into a reaction cell containing the mixed solution, etc., and then moves the stirring member forward and backward or left and right, or rotates the stirring member (hereinafter referred to as a spatula stirring mechanism) to stir the sample, the measuring reagent, or the mixed solution thereof; or an automatic analyzer having a mechanism that irradiates ultrasonic waves from the outside of the reaction cell containing the mixed solution, etc. (hereinafter referred to as an ultrasonic stirring mechanism) to stir the sample, the measuring reagent, or the mixed solution thereof.
[0098] There are no particular restrictions on the automatic analyzer equipped with the above-mentioned scraper stirring mechanism, and examples thereof include automatic analyzer 3500, automatic analyzer 7180 (all manufactured by Hitachi High-Tech Co., Ltd.), JCA-ZS050 automatic analyzer Clearair BioMajesty (registered trademark) ZERO, JCA-BM9130 automatic analyzer Clearair BioMajesty (all manufactured by JEOL Ltd.), TBA (registered trademark)-c16000, TBA-120FR (all manufactured by Canon Medical Systems, Inc.), automatic analyzer AU5800, and automatic analyzer AU680 (all manufactured by Beckman Coulter, Inc.). There are no particular limitations on the automatic analysis device having the ultrasonic stirring mechanism, and examples thereof include automatic analysis device LABOSPECT (registered trademark) 003, automatic analysis device LABOSPECT (registered trademark) 006, and automatic analysis device LABOSPECT (registered trademark) 008α (all manufactured by Hitachi High-Tech Corporation).
[0099] "Using Ultrasonic Waves"
[0100] From the viewpoint of improving sensitivity, the latex agglutination immunoassay method disclosed in the present invention may include a step of treating the sample with ultrasound (ultrasonic treatment). "Treatment with ultrasound" may be stirring with ultrasound as described above. In addition, in addition to treating the sample itself with ultrasound, "treating the sample with ultrasound" may also include, for example, ultrasonic treatment of a solution mixed with a sample and an aqueous medium, ultrasonic treatment of a solution mixed with a sample and a sample dilution reagent described later, ultrasonic treatment of a solution mixed with a sample and a "reagent for latex agglutination immunoassay of sialyl Lewis antigen in a sample" described later, and ultrasonic treatment of a solution mixed with a sample and each reagent contained in a "kit for latex agglutination immunoassay of sialyl Lewis antigen in a sample" described later. Ultrasonic treatment may be performed by any device capable of ultrasonic treatment, such as the above-mentioned device. The time of ultrasonic treatment is not particularly limited as long as the determination method disclosed in the present invention can be performed, and may be, for example, less than 30 seconds, less than 20 seconds, or less than 10 seconds. The time of ultrasonic treatment may also be, for example, more than 5 seconds, more than 3 seconds, more than 1 second, or more than 0.5 seconds. The above values can be combined freely.
[0101] The time for reacting the sialyl Lewis antigen in the sample with the antibody or its antigen-binding fragment that recognizes the sialyl Lewis antigen is not particularly limited as long as it is the time for the determination method of the sialyl Lewis antigen disclosed in the present invention to be performed, for example, it can be more than 10 seconds, more than 20 seconds, more than 30 seconds, more than 1 minute, more than 2 minutes, more than 3 minutes, more than 4 minutes or more than 5 minutes. In addition, the above-mentioned reaction time can also be, for example, less than 1 hour, less than 50 minutes, less than 40 minutes, less than 30 minutes, less than 20 minutes, less than 10 minutes, less than 9 minutes, less than 7 minutes or less than 6 minutes. The above-mentioned numerical values can be freely combined.
[0102] The temperature at which the sialyl Lewis antigen in the sample is reacted with the antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen is not particularly limited as long as it is a temperature at which the method for measuring the sialyl Lewis antigen disclosed herein can be performed, and may be 0° C. or higher, 4° C. or higher, 10° C. or higher, 15° C. or higher, 20° C. or higher, 25° C. or higher, 30° C. or higher, or 37° C. or higher, and may be 50° C. or lower, 45° C. or lower, or 40° C. or lower. The above numerical values may be freely combined.
[0103] The concentration of the latex particles bound to the antibody recognizing the sialyl Lewis antigen or its antigen-binding fragment in the above reaction is not particularly limited as long as it is a concentration that enables the method for measuring the sialyl Lewis antigen disclosed herein to be performed, and may be, for example, 0.001% (w / v) or more, 0.003% (w / v) or more, 0.005% (w / v) or more, 0.01% (w / v) or more, 0.011% (w / v) or more, 0.012% (w / v) or more, or 0.013% (w / v) or more. In addition, the concentration of latex particles bound with an antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof in the above reaction may be, for example, 0.1% (w / v) or less, 0.08% (w / v) or less, 0.06% (w / v) or less, 0.05% (w / v) or less, 0.04% (w / v) or less, 0.03% (w / v) or less, 0.025% (w / v) or less, 0.02% (w / v) or less, or 0.015% (w / v) or less. The above numerical values may be freely combined.
[0104] One embodiment of the method for measuring sialyl Lewis antigen in a sample disclosed herein comprises:
[0105] (1) a step of mixing a sample containing a sialyl Lewis antigen with an aqueous medium; and
[0106] (2) A step of reacting the sialyl Lewis antigen in the sample with latex particles having an average particle size of 200 nm to 400 nm to which an antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen is bound, in the solution obtained in step (1).
[0107] "Process (1)"
[0108] Step (1) is a step of mixing a sample containing a sialyl Lewis antigen with an aqueous medium. In step (1), a sample containing a sialyl Lewis antigen may be added to an aqueous medium and mixed, or an aqueous medium may be added to a sample containing a sialyl Lewis antigen and mixed. The aqueous medium in the above-mentioned step (1) is not particularly limited, and examples thereof include the aforementioned aqueous medium. Examples of the sialyl Lewis antigen include the aforementioned sialyl Lewis antigen, and preferably the DUPAN-2 antigen.
[0109] In step (1), after the sample containing sialyl Lewis antigen is mixed with an aqueous medium, it can be maintained for a certain time and a certain temperature. The time for maintaining the above-mentioned mixed solution is not particularly limited as long as it is a time for the determination method of sialyl Lewis antigen disclosed in the present invention to be performed, for example, it can be more than 10 seconds, more than 20 seconds, more than 30 seconds, more than 1 minute, more than 2 minutes, more than 3 minutes, more than 4 minutes or more than 5 minutes, and can be less than 1 hour, less than 50 minutes, less than 40 minutes, less than 30 minutes, less than 20 minutes, less than 10 minutes, less than 9 minutes, less than 7 minutes or less than 6 minutes. The above numerical values can be freely combined.
[0110] The temperature at which the mixed solution is maintained is not particularly limited as long as it is a temperature at which the method for measuring the sialyl Lewis antigen disclosed herein can be performed, and may be 0° C. or higher, 4° C. or higher, 10° C. or higher, 15° C. or higher, 20° C. or higher, 25° C. or higher, 30° C. or higher, or 37° C. or higher, and may be 50° C. or lower, 45° C. or lower, or 40° C. or lower. The above values may be freely combined.
[0111] "Process (2)"
[0112] Step (2) is a step of reacting the sialyl Lewis antigen in the sample with latex particles to which an antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen is bound, in the solution obtained in step (1).
[0113] In step (2), the sialyl Lewis antigen is reacted with an antibody that recognizes the sialyl Lewis antigen or an antigen-binding fragment thereof to generate a complex comprising the sialyl Lewis antigen and latex particles bound to the antibody that recognizes the sialyl Lewis antigen or an antigen-binding fragment thereof. As described above, the sialyl Lewis antigen in the biological sample is a multivalent antigen, so even when a single antibody is used, a complex comprising the sialyl Lewis antigen and latex particles bound to the antibody that recognizes the sialyl Lewis antigen or an antigen-binding fragment thereof is generated.
[0114] In step (2), the solution obtained in step (1) may be added to latex particles to which an antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen is bound, and the reaction may be carried out, or latex particles to which an antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen is bound may be added to the solution obtained in step (1), and the reaction may be carried out. As the latex particles to which an antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen is bound, for example, the latex particles to which an antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen is bound may be the aforementioned latex particles.
[0115] In step (2), two or more antibodies or antigen-binding fragments thereof that recognize sialyl Lewis antigen may be used. When two antibodies or antigen-binding fragments thereof that recognize sialyl Lewis antigen are used, step (2) may be performed as follows. In addition, the assay method in the present disclosure may also include step (3) described later after step (2A).
[0116] (2A) A step of reacting the sialyl Lewis antigen in the sample with latex particles bound to a first antibody recognizing the sialyl Lewis antigen or an antigen-binding fragment thereof, and latex particles bound to a second antibody recognizing the sialyl Lewis antigen or an antigen-binding fragment thereof in the solution obtained in step (1).
[0117] In step (2A), the sialyl Lewis antigen is reacted with a first antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen and a second antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen to generate a complex comprising the sialyl Lewis antigen, latex particles bound to the first antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen, and latex particles bound to the second antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen.
[0118] In step (2A), the latex particles bound with the first antibody recognizing sialyl Lewis antigen or its antigen-binding fragment and the latex particles bound with the second antibody recognizing sialyl Lewis antigen or its antigen-binding fragment may be the same or different.
[0119] The reaction in step (2A) is not particularly limited as long as it is a reaction for generating the above-mentioned complex. For example, after reacting the sialyl Lewis antigen with latex particles bound to the first antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen to generate a complex comprising the sialyl Lewis antigen and the latex particles bound to the first antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen, latex particles bound to the second antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen may be added to react. Alternatively, the sialyl Lewis antigen, the latex particles bound to the first antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen, and the latex particles bound to the second antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen may be mixed and reacted.
[0120] When the sialyl Lewis antigen is mixed with latex particles bound to a first antibody or its antigen-binding fragment that recognizes the sialyl Lewis antigen and latex particles bound to a second antibody or its antigen-binding fragment that recognizes the sialyl Lewis antigen to react, the order of adding them is not limited. For example, latex particles bound to a first antibody or its antigen-binding fragment that recognizes the sialyl Lewis antigen and latex particles bound to a second antibody or its antigen-binding fragment that recognizes the sialyl Lewis antigen can be added to the sialyl Lewis antigen. Alternatively, latex particles bound to a first antibody or its antigen-binding fragment that recognizes the sialyl Lewis antigen can be mixed with the sialyl Lewis antigen, and then latex particles bound to a second antibody or its antigen-binding fragment that recognizes the sialyl Lewis antigen can be added. Alternatively, the sialyl Lewis antigen can be added after latex particles bound to a first antibody or its antigen-binding fragment that recognizes the sialyl Lewis antigen are mixed. Alternatively, the sialyl Lewis antigen can be added after latex particles bound to a first antibody or its antigen-binding fragment that recognizes the sialyl Lewis antigen are mixed with latex particles bound to a second antibody or its antigen-binding fragment that recognizes the sialyl Lewis antigen.
[0121] As described above, step (2A) can be performed by dividing into the following step (2A-1) and step (2A-2). In addition, the measurement method in the present disclosure may include the step (3) described below after step (2A-2).
[0122] (2A-1) a step of reacting the sialyl Lewis antigen in the sample with latex particles bound to a first antibody recognizing the sialyl Lewis antigen or an antigen-binding fragment thereof in the solution obtained in step (1) to generate a complex 1 comprising the sialyl Lewis antigen and latex particles bound to the first antibody recognizing the sialyl Lewis antigen or an antigen-binding fragment thereof; and
[0123] (2A-2) The complex 1 generated in step (2A-1) is reacted with latex particles bound to a second antibody that recognizes sialyl Lewis antigen or an antigen-binding fragment thereof in an aqueous medium to generate a complex 2 comprising sialyl Lewis antigen, latex particles bound to a first antibody that recognizes sialyl Lewis antigen or an antigen-binding fragment thereof, and latex particles bound to a second antibody that recognizes sialyl Lewis antigen or an antigen-binding fragment thereof.
[0124] The reaction time of step (2) or step (2A) is not particularly limited as long as it is a time that can carry out the determination method of the sialyl Lewis antigen disclosed in the present invention, for example, it can be more than 10 seconds, more than 20 seconds, more than 30 seconds, more than 1 minute, more than 2 minutes, more than 3 minutes, more than 4 minutes or more than 5 minutes, and can be less than 1 hour, less than 50 minutes, less than 40 minutes, less than 30 minutes, less than 20 minutes, less than 10 minutes, less than 9 minutes, less than 7 minutes or less than 6 minutes. The above numerical values can be freely combined. Wherein, when step (2A) is divided into step (2A-1) and step (2A-2) for carrying out, the above reaction time can be the reaction time of each step, or it can be the total of the reaction time of each step.
[0125] The reaction temperature of step (2) or step (2A) is not particularly limited as long as it is a temperature at which the method for measuring the sialyl Lewis antigen disclosed in the present invention can be performed, and may be above 0°C, above 4°C, above 10°C, above 15°C, above 20°C, above 25°C, above 30°C, or above 37°C, and may be below 50°C, below 45°C, or below 40°C. The above numerical values may be freely combined. In the case where step (2A) is divided into step (2A-1) and step (2A-2), the above reaction temperature may be the same or different in each step.
[0126] The concentration of the latex particles to which the antibody recognizing the sialyl Lewis antigen or the antigen-binding fragment thereof is bound in step (2) or step (2A) is not particularly limited as long as it is a concentration that enables the method for measuring the sialyl Lewis antigen of the present disclosure to be performed, and may be, for example, 0.001% (w / v) or more, 0.003% (w / v) or more, 0.005% (w / v) or more, 0.01% (w / v) or more, 0.011% (w / v) or more, 0.012% (w / v) or more, or 0.013% (w / v) or more. In addition, the concentration of latex particles bound to an antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen in the above step (2) or step (2A) can also be, for example, 0.1% (w / v) or less, 0.08% (w / v) or less, 0.06% (w / v) or less, 0.05% (w / v) or less, 0.04% (w / v) or less, 0.03% (w / v) or less, 0.025% (w / v) or less, 0.02% (w / v) or less, or 0.015% (w / v) or less. The above numerical values can be freely combined. Among them, in step (2A), the concentration of latex particles bound to an antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen refers to the total concentration of latex particles bound to a first antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen and the concentration of latex particles bound to a second antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen.
[0127] The step (2) is preferably carried out in an aqueous medium. Examples of the aqueous medium include the aforementioned aqueous medium. Alternatively, the step (2) may be carried out in the presence of the aforementioned salts, sugars, proteins, and the like.
[0128] After the above-mentioned step (1) and / or after the step (2) or the step (2A), a step of treating with ultrasound may be included. The ultrasound treatment may be the same as the aforementioned ultrasound treatment. When the step (2A) is divided into the step (2A-1) and the step (2A-2) for carrying out, a step of treating with ultrasound may be included after the step (2A-1) and / or after the step (2A-2).
[0129] "Metal ions"
[0130] The above-mentioned step (1) and / or step (2) or step (2A) may be carried out in the presence of metal ions. When step (2A) is divided into step (2A-1) and step (2A-2), step (2A-1) and / or step (2A-2) may be carried out in the presence of metal ions.
[0131] In the present disclosure, the metal ion is not particularly limited as long as it can be used in the measurement method of the sialyl Lewis antigen of the present disclosure or can be used in the measurement reagent or measurement kit of the present disclosure described later, and examples thereof include sodium ion, magnesium ion, manganese ion, zinc ion, etc. In the measurement method of the present disclosure, the valence of the metal ion is not particularly limited, and examples thereof include monovalent, divalent, trivalent, tetravalent, etc., and from the viewpoint of improving sensitivity, divalent or higher valence is preferred.
[0132] Examples of divalent or higher valent metal ions include alkaline earth metal ions such as beryllium ion, magnesium ion, calcium ion, strontium ion, and barium ion; and first transition element ions such as titanium ion, chromium ion, manganese ion, iron ion, cobalt ion, nickel ion, copper ion, and zinc ion.
[0133] The concentration of the metal ion in the above step is not particularly limited as long as it is a concentration that enables the measurement method of the sialyl Lewis antigen disclosed herein to be performed, and may be, for example, 0.01 mmol / L or more, 0.02 mmol / L or more, 0.03 mmol / L or more, 0.04 mmol / L or more, 0.05 mmol / L or more, 0.06 mmol / L or more, 0.07 mmol / L or more, 0.08 mmol / L or more, 0.09 mmol / L or more, 0.1 mmol / L or more, 0.2 mmol / L or more, 0.3 mmol / L or more, 0.4 mmol / L or more, 0.5 mmol / L or more, 0.6 mmol / L or more, 0.7 mmol / L or more, 0.8 mmol / L or more, 0.9 mmol / L or more, 1 mmol / L or more, 2 mmol / L or more, 3 mmol / L or more, 4 mmol / L or more, 5 mmol / L or more, 6 mmol / L or more, 7 mmol / L or more, 8 mmol / L or more, or 9 mmol / L or more. In addition, the concentration of the metal ions in the above-mentioned process can also be, for example, less than 1000mmol / L, less than 900mmol / L, less than 800mmol / L, less than 700mmol / L, less than 600mmol / L, less than 500mmol / L, less than 400mmol / L, less than 300mmol / L, less than 250mmol / L, less than 200mmol / L, less than 150mmol / L, less than 140mmol / L, less than 130mmol / L, less than 120mmol / L, less than 110mmol / L, less than 100mmol / L, less than 90mmol / L, less than 80mmol / L, less than 75mmol / L, less than 70mmol / L, less than 60mmol / L, less than 50mmol / L, less than 40mmol / L, less than 30mmol / L, less than 20mmol / L or less than 10mmol / L.
[0134] The above numerical values can be freely combined. In the above process, there can be one metal ion or two or more metal ions. When there are two or more metal ions, the above concentration refers to the total concentration of the two or more metal ions. The above metal ion concentration can be the same concentration or different concentrations in each process.
[0135] The antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen (including the first antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen, or the second antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen) can be directly bound to the latex particles by the aforementioned physical adsorption and / or chemical binding, or can be indirectly bound to the latex particles. As the indirect binding method, there can be mentioned a method of binding the first antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen, or the second antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen to the latex particles by utilizing the specific binding of the aforementioned group of affinity substances, and a method of binding to the latex particles by covalent bonds through a linker molecule.
[0136] When a set of affinity substances is used, latex particles to which an antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen or antigen-binding fragment thereof is bound, which is bound to one (A) of the set of affinity substances, can be generated. As a combination of Aa, the aforementioned combinations and the like can be cited. As a linker molecule, the aforementioned molecules and the like can be cited.
[0137] In step (2) or step (2A), the latex particles may be bound to an antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen in an aqueous medium. In this case, the method for binding the antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen to the latex particles may include, for example, the aforementioned binding method.
[0138] "Process (3)"
[0139] The measuring method in the present disclosure may further include the following step (3) after the above step (2).
[0140] (3) A step of measuring aggregation of latex particles generated by the reaction of the sialyl Lewis antigen with latex particles to which an antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen is bound, and obtaining a measured value.
[0141] Step (3) is a step of measuring the aggregation of latex particles accompanying the formation of the composite in step (2), the composite in step (2A), or the composite 2 in step (2A-2) by an optical method. Examples of the method for optically measuring aggregation include a method of measuring absorbance, scattered light intensity, or transmitted light intensity using an optical device.
[0142] The absorbance measurement wavelength is usually 340nm to 1000nm, preferably 500nm to 900nm. The time for photometry of the latex aggregation reaction can be photometrically measured based on the rate of change per unit time or the amount of change in a certain time. For example, when measuring the absorbance, the photometry can be performed based on the rate of change of absorbance per unit time from 30 seconds to 5 minutes after the start of the latex aggregation reaction, or the amount of change of absorbance in a certain time. The reaction temperature is preferably 10 to 50°C, more preferably 20 to 40°C. The reaction time can be appropriately determined, for example, it can be measured in a general automatic analyzer with a reaction time of 5 to 15 minutes.
[0143] In addition to the above steps (1) to (3), the concentration of sialyl Lewis antigen in the sample can be determined by performing the following steps (4) and (5).
[0144] (4) using a sialyl Lewis antigen of known concentration as a sample, performing the above steps (1) to (3), and preparing a standard curve showing the relationship between the sialyl Lewis antigen concentration and the measured value;
[0145] (5) A step of determining the concentration of the sialyl Lewis antigen in the sample based on the calibration curve prepared in step (4) and the measurement value obtained in the measurement in step (3).
[0146] Examples of sialyl Lewis antigens of known concentration include sialyl Lewis antigen solutions obtained by diluting sialyl Lewis antigens derived from serum of cancer patients or sialyl Lewis antigens derived from cultured cancer cells with PBS, etc. Sialyl Lewis antigens of known concentrations may be prepared at a plurality of concentrations.
[0147] The concentration of the sialyl Lewis antigen in the sialyl Lewis antigen with a known concentration is not particularly limited as long as it is a concentration that can measure the sialyl Lewis antigen, and may be, for example, 1 U / mL or more, 5 U / mL or more, 6 U / mL or more, 7 U / mL or more, 8 U / mL or more, 9 U / mL or more, 10 U / mL or more, 20 U / mL or more, 25 U / mL or more, 30 U / mL or more, 40 U / mL or more, 50 U / mL or more, 60 U / mL or more, 70 U / mL or more, 80 U / mL or more, 90 U / mL or more L or more, 100 U / mL or more, 200 U / mL or more, 300 U / mL or more, 400 U / mL or more, 500 U / mL or more, 600 U / mL or more, 700 U / mL or more, 800 U / mL or more, 900 U / mL or more, 1000 U / mL or more, 1100 U / mL or more, 1200 U / mL or more, 1300 U / mL or more, 1400 U / mL or more, 1500 U / mL or more, 1600 U / mL or more, 1700 U / mL or more, or 1800 U / mL or more. In addition, the concentration of the sialyl Lewis antigen in the sialyl Lewis antigen of known concentration may be, for example, 15000 U / mL or less, 14000 U / mL or less, 13000 U / mL or less, 12000 U / mL or less, 11000 U / mL or less, 10000 U / mL or less, 9000 U / mL or less, 8000 U / mL or less, 7000 U / mL or less, 6000 U / mL or less, 5000 U / mL or less, 4000 U / mL or less, 3700 U / mL or less, 3600 U / mL or less. The above values may be freely combined.
[0148] It should be noted that the concentration unit "U / mL" of the sialyl Lewis antigen is defined for each of the aforementioned sialyl Lewis antigens. For example, the concentration unit "U / mL" of the DUPAN-2 antigen is defined as "when the serum of a specific pancreatic cancer patient is measured by competitive radioimmunoassay, the concentration of the DUPAN-2 antigen contained in the serum is recorded as 1000 U / mL" (Metzgar et al., "Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma", Proceedings of the National Academy of Sciences of the United States of America, 1984, Vol. 81, pp. 5242-5246).
[0149] "Reagent for latex agglutination immunoassay of sialyl Lewis antigen in a sample"
[0150] The reagent for latex agglutination immunoassay of sialyl Lewis antigen in a sample disclosed herein comprises latex particles having an average particle size of 200 nm to 400 nm to which an antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen is bound. The assay reagent disclosed herein is the reagent used in the aforementioned assay method.
[0151] One embodiment (embodiment 1) of the assay reagent of the present disclosure relates to a reagent for latex agglutination immunoassay of a sialyl Lewis antigen in a sample, the reagent comprising latex particles and an antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen.
[0152] In Embodiment 1, latex particles and an antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen may be bound via two affinity substances. Examples of methods for binding an antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen to latex particles include the above-mentioned binding methods.
[0153] Another embodiment (embodiment 2) of the measuring reagent of the present disclosure relates to a measuring reagent for sialyl Lewis antigen in a sample, comprising latex particles to which an antibody recognizing sialyl Lewis antigen or an antigen-binding fragment thereof is bound.
[0154] Another embodiment (embodiment 3) of the measuring reagent of the present disclosure relates to a measuring reagent for sialyl Lewis antigen in a sample, comprising latex particles to which a first antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen is bound, and latex particles to which a second antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen is bound.
[0155] In the assay reagents of Embodiments 1 to 3, the latex particles and the latex particles bound with an antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen (including latex particles bound with a first antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen, and latex particles bound with a second antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen) can be, for example, the latex particles bound with an antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen as described above. In addition, in the assay reagent of the present disclosure, the sialyl Lewis antigen as the assay target component can be, for example, the sialyl Lewis antigen as described above, preferably, the DUPAN-2 antigen.
[0156] The antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen in the assay reagents of embodiments 2 and 3 may be directly bound to the latex particles by physical adsorption and / or chemical binding as described above, or may be indirectly bound to the latex particles. Examples of indirect binding methods include a method of binding the antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen to the latex particles by utilizing the specific binding of the aforementioned group of affinity substances; and a method of binding to the latex particles by covalent bonds via a linker molecule.
[0157] When a set of affinity substances is used, latex particles to which an antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen or antigen-binding fragment thereof is bound, which is bound to one (A) of the set of affinity substances, can be generated. As a combination of Aa, the aforementioned combinations and the like can be cited. As a linker molecule, the aforementioned molecules and the like can be cited.
[0158] The concentration of the latex particles in the assay reagents of Embodiments 1 to 3 is not particularly limited as long as it is a concentration that enables the assay method of the sialyl Lewis antigen disclosed herein to be performed, and may be, for example, 0.001% (w / v) or more, 0.003% (w / v) or more, 0.005% (w / v) or more, 0.008% (w / v) or more, 0.01% (w / v) or more, 0.015% (w / v) or more, 0.02% (w / v) or more, 0.03% (w / v) or more, 0.04% (w / v) or more, or 0.05% (w / v) or more. The concentration of the latex particles in the measuring reagents of Embodiments 1 to 3 may be, for example, 1% (w / v) or less, 0.8% (w / v) or less, 0.5% (w / v) or less, 0.3% (w / v) or less, 0.2% (w / v) or less, 0.1% (w / v) or less, 0.09% (w / v) or less, 0.08% (w / v) or less, 0.07% (w / v) or less, or 0.06% (w / v) or less. The above numerical values may be freely combined.
[0159] In the reagent of embodiment 3, the concentration of latex particles bound to an antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof refers to the total concentration of latex particles bound to a first antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof and the concentration of latex particles bound to a second antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof.
[0160] The assay reagent disclosed herein is for latex agglutination immunoassay, and the latex agglutination immunoassay may include a step of treating the sample with the aforementioned ultrasonic wave. Therefore, the assay reagent disclosed herein may also be a reagent for use in an analysis device having an ultrasonic wave processing function. In addition, the assay reagent disclosed herein may also include an instruction manual recording the treatment of the sample with ultrasonic wave.
[0161] The analysis device having an ultrasonic processing function is not particularly limited as long as it has an ultrasonic processing function, and an example thereof includes an automatic analysis device having the above-mentioned ultrasonic stirring mechanism.
[0162] The above-mentioned instructions are not particularly limited as long as they describe that the sample is treated with ultrasonic waves, and examples thereof include instructions describing a device capable of the above-mentioned treatment with ultrasonic waves.
[0163] The measuring reagent of the present disclosure may contain the aforementioned metal ions, and preferably contains divalent or higher-valent metal ions. The concentration of the metal ion in the assay reagent of the present disclosure is not particularly limited as long as it is a concentration that enables the assay method of the sialyl Lewis antigen of the present disclosure to be performed, and for example, it may be 0.01 mmol / L or more, 0.02 mmol / L or more, 0.03 mmol / L or more, 0.04 mmol / L or more, 0.05 mmol / L or more, 0.06 mmol / L or more, 0.07 mmol / L or more, 0.08 mmol / L or more, 0.09 mmol / L or more, 0.1 mmol / L or more, 0.2 mmol / L or more, 0.3 mmol / L or more, 0.4 mmol / L or more, 0.5 mmol / L or more, 0.6 mmol / L or more, 0.7 mmol / L or more, 0.8 mmol / L or more, 0.9 mmol / L or more, 1 mmol / L or more, 2 mmol / L or more, 3 mmol / L or more, 4 mmol / L or more, 5 mmol / L or more, 6 mmol / L or more, 7 mmol / L or more, 8 mmol / L or more, or 9 mmol / L or more. In addition, the concentration of the metal ion in the measuring reagent of the present invention can also be, for example, 1000mmol / L or less, 900mmol / L or less, 800mmol / L or less, 700mmol / L or less, 600mmol / L or less, 500mmol / L or less, 400mmol / L or less, 300mmol / L or less, 250mmol / L or less, 200mmol / L or less, 150mmol / L or less, 140mmol / L or less, 130mmol / L or less, 120mmol / L or less, 110mmol / L or less, 100mmol / L or less, 90mmol / L or less, 80mmol / L or less, 75mmol / mL or less, 70mmol / L or less, 60mmol / L or less, 50mmol / L or less, 40mmol / L or less, 30mmol / L or less, 20mmol / L or less, or 10mmol / L or less.
[0164] The above values can be freely combined. In the assay reagent disclosed herein, one metal ion may be contained, or two or more metal ions may be contained. When two or more metal ions are contained, the above concentration refers to the total concentration of the two or more metal ions.
[0165] The time for reacting the sialyl Lewis antigen in the sample with the antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen can be the same as the aforementioned reaction time, for example, can be more than 10 seconds, more than 20 seconds, more than 30 seconds, more than 1 minute, more than 2 minutes, more than 3 minutes, more than 4 minutes or more than 5 minutes. In addition, the above-mentioned reaction time can also be, for example, less than 1 hour, less than 50 minutes, less than 40 minutes, less than 30 minutes, less than 20 minutes, less than 10 minutes, less than 9 minutes, less than 7 minutes or less than 6 minutes. The above-mentioned numerical values can be freely combined.
[0166] The temperature for reacting the sialyl Lewis antigen in the sample with the antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen may be the same as the aforementioned reaction temperature, and may be 0° C. or higher, 4° C. or higher, 10° C. or higher, 15° C. or higher, 20° C. or higher, 25° C. or higher, 30° C. or higher, or 37° C. or higher, and may be 50° C. or lower, 45° C. or lower, or 40° C. or lower. The above numerical values may be freely combined.
[0167] The assay reagent disclosed herein may be in a freeze-dried state or in a liquid state. When a freeze-dried assay reagent is used, it is dissolved in an aqueous medium before the assay to make it liquid for the assay. There are no particular restrictions on the aqueous medium used for dissolution, and examples thereof include the aforementioned aqueous medium. The aqueous medium may contain the aforementioned salts, sugars, proteins, surfactants, and the like.
[0168] In the liquid assay reagent, at least one selected from latex particles, a first antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen, and a second antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen are mixed in an aqueous medium. The aqueous medium is not particularly limited, and examples thereof include the aforementioned aqueous medium. The aqueous medium may contain the aforementioned salts, sugars, proteins, surfactants, and the like.
[0169] "Kit for latex agglutination immunoassay of sialyl Lewis antigen in a sample"
[0170] From the viewpoint of storage, transportation, distribution, etc., the reagent for latex agglutination immunoassay of sialyl Lewis antigen in the sample of the present disclosure may be in the form of a kit.
[0171] The kit for latex agglutination immunoassay of sialyl Lewis antigen in a sample disclosed herein comprises latex particles having an average particle size of 200 nm to 400 nm to which an antibody or an antigen-binding fragment thereof that recognizes sialyl Lewis antigen is bound. In addition, the kit for assay disclosed herein is a kit used in the aforementioned latex agglutination immunoassay method of sialyl Lewis antigen in a sample.
[0172] Hereinafter, the method of the assay kit for sialyl Lewis antigen in the sample disclosed herein is exemplified. It should be noted that, in the method of the assay kit described later, the aqueous medium, the latex particles bound to the antibody or its antigen-binding fragment that recognizes sialyl Lewis antigen (including the latex particles bound to the first antibody or its antigen-binding fragment that recognizes sialyl Lewis antigen, and the latex particles bound to the second antibody or its antigen-binding fragment that recognizes sialyl Lewis antigen) can be, for example, the aforementioned aqueous medium, sialyl Lewis antigen, and the latex particles bound to the antibody or its antigen-binding fragment that recognizes sialyl Lewis antigen. In the assay kit disclosed herein, the sialyl Lewis antigen as the assay object component can be, for example, the aforementioned sialyl Lewis antigen, preferably the DUPAN-2 antigen.
[0173] [Assay kit (1)]
[0174] A test kit, comprising:
[0175] Reagent 1A comprising an aqueous medium; and
[0176] The second reagent A comprises latex particles to which an antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof is bound.
[0177] [Assay kit (2)]
[0178] A test kit, comprising:
[0179] Reagent 1B comprising an aqueous medium; and
[0180] The second B reagent contains latex particles to which a first antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen is bound, and latex particles to which a second antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen is bound.
[0181] [Assay kit (3)]
[0182] A test kit, comprising:
[0183] A 1C reagent comprising an aqueous medium;
[0184] a second reagent C comprising latex particles to which a first antibody or an antigen-binding fragment thereof that recognizes a sialyl Lewis antigen is bound; and
[0185] The 3C reagent contains latex particles to which a second antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof is bound.
[0186] The antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen (including the first antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen, or the second antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen) can be directly bound to the latex particles by the aforementioned physical adsorption and / or chemical binding, or can be indirectly bound to the latex particles. As the indirect binding method, there can be cited a method of binding the antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen to the latex particles by utilizing the specific binding of the aforementioned group of affinity substances; a method of binding to the latex particles by covalent bonds via a linker molecule, etc.
[0187] When a set of affinity substances is used, latex particles to which an antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen or antigen-binding fragment thereof is bound, which is bound to one (A) of the set of affinity substances, can be generated. As a combination of Aa, the aforementioned combinations and the like can be cited. As a linker molecule, the aforementioned molecules and the like can be cited.
[0188] The concentration of latex particles to which an antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof is bound in the 2A reagent or the 2B reagent is not particularly limited as long as it is a concentration at which the method for measuring a sialyl Lewis antigen of the present disclosure can be performed, and may be, for example, 0.001% (w / v) or more, 0.003% (w / v) or more, 0.005% (w / v) or more, 0.008% (w / v) or more, 0.01% (w / v) or more, 0.015% (w / v) or more, 0.02% (w / v) or more, 0.03% (w / v) or more, 0.04% (w / v) or more, or 0.05% (w / v) or more. In addition, the concentration of latex particles bound with an antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof in the 2A reagent or the 2B reagent may be, for example, 1% (w / v) or less, 0.8% (w / v) or less, 0.5% (w / v) or less, 0.3% (w / v) or less, 0.2% (w / v) or less, 0.1% (w / v) or less, 0.09% (w / v) or less, 0.08% (w / v) or less, 0.07% (w / v) or less, or 0.06% (w / v) or less. The above values may be freely combined.
[0189] In the 2B reagent, the concentration of latex particles bound to an antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof refers to the total concentration of latex particles bound to a first antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof and the concentration of latex particles bound to a second antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof.
[0190] The concentration of latex particles to which an antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof is bound in the 2C reagent or the 3C reagent is not particularly limited as long as it is a concentration at which the method for measuring a sialyl Lewis antigen of the present disclosure can be performed, and may be, for example, 0.0005% (w / v) or more, 0.001% (w / v) or more, 0.002% (w / v) or more, 0.003% (w / v) or more, 0.005% (w / v) or more, 0.008% (w / v) or more, 0.01% (w / v) or more, 0.015% (w / v) or more, 0.02% (w / v) or more, or 0.025% (w / v) or more. In addition, the concentration of latex particles bound to an antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof in the 2C reagent or the 3C reagent may be, for example, 1% (w / v) or less, 0.8% (w / v) or less, 0.5% (w / v) or less, 0.3% (w / v) or less, 0.2% (w / v) or less, 0.1% (w / v) or less, 0.09% (w / v) or less, 0.08% (w / v) or less, 0.07% (w / v) or less, 0.06% (w / v) or less, 0.05% (w / v) or less, 0.04% (w / v) or less, or 0.03% (w / v) or less. The above numerical values may be freely combined.
[0191] The assay kit disclosed herein is for latex agglutination immunoassay, and the latex agglutination immunoassay may include a step of treating the sample with the aforementioned ultrasonic wave. Therefore, it may also be a kit for use in an analysis device having an ultrasonic wave processing function. In addition, the assay kit disclosed herein may also include instructions recording the treatment of the sample with ultrasonic wave.
[0192] The analysis device having the ultrasonic processing function is not particularly limited as long as it has the ultrasonic processing function, and an example thereof includes an automatic analysis device having the above-mentioned ultrasonic stirring mechanism.
[0193] The above-mentioned instructions are not particularly limited as long as they describe that the sample is treated with ultrasonic waves, and examples thereof include instructions describing a device capable of the above-mentioned treatment with ultrasonic waves.
[0194] The first reagent and / or the second reagent may contain the aforementioned metal ions, preferably divalent or higher metal ions. In the case of an assay kit containing a third reagent, the third reagent may contain the aforementioned metal ions in addition to the first reagent and / or the second reagent.
[0195] The concentration of the metal ion in the constituent reagents of the assay kit of the present disclosure is not particularly limited as long as it is a concentration at which the assay method of the sialyl Lewis antigen of the present disclosure can be performed, and for example, it may be 0.01 mmol / L or more, 0.02 mmol / L or more, 0.03 mmol / L or more, 0.04 mmol / L or more, 0.05 mmol / L or more, 0.06 mmol / L or more, 0.07 mmol / L or more, 0.08 mmol / L or more, 0.09 mmol / L or more, 0.1 mmol / L or more, 0.2 mmol / L or more, 0.3 mmol / L or more, 0.4 mmol / L or more, 0.5 mmol / L or more, 0.6 mmol / L or more, 0.7 mmol / L or more, 0.8 mmol / L or more, 0.9 mmol / L or more, 1 mmol / L or more, 2 mmol / L or more, 3 mmol / L or more, 4 mmol / L or more, 5 mmol / L or more, 6 mmol / L or more, 7 mmol / L or more, 8 mmol / L or more, or 9 mmol / L or more. In addition, the concentration of the metal ion in the constituent reagent of the assay kit of the present disclosure may be, for example, 1000mmol / L or less, 900mmol / L or less, 800mmol / L or less, 700mmol / L or less, 600mmol / L or less, 500mmol / L or less, 400mmol / L or less, 300mmol / L or less, 250mmol / L or less, 200mmol / L or less, 150mmol / L or less, 140mmol / L or less, 130mmol / L or less, 120mmol / L or less, 110mmol / L or less, 100mmol / L or less, 90mmol / L or less, 80mmol / L or less, 75mmol / L or less, 70mmol / L or less, 60mmol / L or less, 50mmol / L or less, 40mmol / L or less, 30mmol / L or less, 20mmol / L or less, or 10mmol / L or less. The above numerical values may be freely combined.
[0196] Among them, the constituent reagents of the assay kit disclosed herein may contain one metal ion or two or more metal ions. When containing two or more metal ions, the above concentration refers to the sum of the concentrations of the two or more metal ions. The above metal ion concentrations may be the same concentration in each reagent or different concentrations.
[0197] The time for reacting the sialyl Lewis antigen in the sample with the antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen can be the same as the aforementioned reaction time, for example, can be more than 10 seconds, more than 20 seconds, more than 30 seconds, more than 1 minute, more than 2 minutes, more than 3 minutes, more than 4 minutes or more than 5 minutes. In addition, the above-mentioned reaction time can also be, for example, less than 1 hour, less than 50 minutes, less than 40 minutes, less than 30 minutes, less than 20 minutes, less than 10 minutes, less than 9 minutes, less than 7 minutes or less than 6 minutes. The above-mentioned numerical values can be freely combined.
[0198] The temperature for reacting the sialyl Lewis antigen in the sample with the antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen may be the same as the aforementioned reaction temperature, and may be 0° C. or higher, 4° C. or higher, 10° C. or higher, 15° C. or higher, 20° C. or higher, 25° C. or higher, 30° C. or higher, or 37° C. or higher, and may be 50° C. or lower, 45° C. or lower, or 40° C. or lower. The above numerical values may be freely combined.
[0199] The constituent reagents of the assay kit disclosed herein may be in a freeze-dried state or in a liquid state. When the constituent reagents of the assay kit are in a freeze-dried state, they are dissolved in an aqueous medium before the assay to make them in a liquid state for the assay. Examples of the aqueous medium include the aforementioned aqueous medium. The aqueous medium may contain the aforementioned salts, sugars, proteins, surfactants, etc.
[0200] When the reagents constituting the assay kit are in liquid form, at least one selected from the first antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen, and the second antibody or antigen-binding fragment thereof that recognizes sialyl Lewis antigen is dissolved or mixed in an aqueous medium. Examples of the aqueous medium include the aforementioned aqueous medium. The aqueous medium may contain the aforementioned salts, sugars, proteins, surfactants, and the like.
[0201] The above-mentioned assay kits (1) to (3) may include, as a reagent for diluting a sample, a sample dilution reagent containing an aqueous medium. As an aqueous medium, for example, the above-mentioned aqueous medium may be mentioned. The aqueous medium may contain the above-mentioned salts, sugars, proteins, surfactants, etc. In addition, the above-mentioned assay kits (1) to (3) may include the above-mentioned cleaning solution, a standard substance reagent containing a sialyl Lewis antigen of a known concentration as a standard substance, an instruction manual recording the assay method disclosed in the present invention, etc.
[0202] Regarding sialyl Lewis antigen with known concentrations as a reference substance, examples thereof include a sialyl Lewis antigen solution obtained by diluting sialyl Lewis antigen derived from blood or sialyl Lewis antigen derived from cultured cancer cells with PBS. In the kit of the present disclosure, a plurality of sialyl Lewis antigens with known concentrations may be included. The concentration of sialyl Lewis antigen in the sialyl Lewis antigen with known concentrations as a reference substance may be, for example, the aforementioned concentration or the like.
[0203] Examples
[0204] Hereinafter, the present disclosure will be described in more detail by way of examples, but these are not intended to limit the scope of the present disclosure in any way. In addition, in the following examples, the following reagents from the following manufacturers were used.
[0205] Carboxyl-modified polystyrene latex (average particle diameters of 100 nm, 200 nm, 300 nm, and 400 nm) (manufactured by Fujikura Kasei Co., Ltd.), Sulfo-NHS (manufactured by Thermo Fisher Scientific), EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) (manufactured by Thermo Fisher Scientific), 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) (manufactured by Dojindo Laboratories), N,N-bis(2-hydroxyethyl)glycine (Bicine) (manufactured by Dojindo Laboratories), bovine serum albumin (BSA) (manufactured by Bovogen), sodium chloride (manufactured by FUJIFILM Wako Pure Chemical Corporation), magnesium sulfate (manufactured by FUJIFILM Wako Pure Chemical Corporation), DUPAN-2 antigen assay kit "Deteminer (registered trademark) DUPAN-2N" (manufactured by Minaris Medical).
[0206] <Preparation of latex particles conjugated with DUPAN-2 antibody>
[0207] Using carboxyl-modified polystyrene latex (average particle diameters of 100 nm, 200 nm, 300 nm, or 400 nm), EDC, Sulfo-NHS, and DUPAN-2 antibody, the DUPAN-2 antibody was conjugated with the latex particles according to a conventional method.
[0208] <Preparation of DUPAN-2 antigen solution>
[0209] The DUPAN-2 antigen content was calculated using the DUPAN-2 antigen determination kit "Deteminer (registered trademark) DUPAN-2N" for a solution of DUPAN-2 antigen purified from the culture supernatant of human pancreatic cancer cultured cells HPAF (HPAF-II). The DUPAN-2 antigen solution whose content was calculated was diluted with the sample diluent attached to "Deteminer (registered trademark) DUPAN-2N" to prepare a DUPAN-2 antigen solution.
[0210] [Experimental Example 1] Evaluation of the relationship between the average particle size of latex particles and the measurement sensitivity
[0211] <Preparation of Assay Kit>
[0212] Assay kits 1 to 3 (Examples 1 to 3) containing the first and second reagents of the following compositions were prepared. In the assay kits 1 to 3, the average particle size of the DUPAN-2 antibody-bound latex particles contained in the second reagent was different, namely, 200 nm, 300 nm, and 400 nm.
[0213] (Reagent No. 1)
[0214] HEPES 50mmol / L
[0215] BSA 1%(w / v)
[0216] Sodium chloride 150mmol / L
[0217] The pH was adjusted to 7.0 with an appropriate amount of sodium hydroxide.
[0218] (Second reagent)
[0219] Bicine 10mmol / L
[0220] DUPAN-2 antibody-bound latex particles (average particle size: 200, 300, 400 nm)
[0221] The pH was adjusted to 8.0 with an appropriate amount of sodium hydroxide. In addition, the DUPAN-2 antibody-bound latex particles were added so that the absorbance of the second reagent at 570 nm was 0.5.
[0222] A measurement kit A (Comparative Example 1) containing the first reagent and the second reagent having the following composition was prepared.
[0223] (Reagent No. 1)
[0224] HEPES 50mmol / L
[0225] BSA 1%(w / v)
[0226] Sodium chloride 150mmol / L
[0227] The pH was adjusted to 7.0 with an appropriate amount of sodium hydroxide.
[0228] (Second reagent)
[0229] Bicine 10mmol / L
[0230] DUPAN-2 antibody-bound latex particles (average particle size 100 nm)
[0231] The pH was adjusted to 8.0 with an appropriate amount of sodium hydroxide. In addition, the DUPAN-2 antibody-bound latex particles were added so that the absorbance of the second reagent at 570 nm was 0.5.
[0232] <Evaluation of Relationship between Average Particle Size of Latex Particles and Measurement Sensitivity>
[0233] The DUPAN-2 antigen was measured according to the following procedure using the automatic analyzer 3500 (manufactured by Hitachi High-Tech Co., Ltd.), the assay kits 1 to 3 (Examples 1 to 3) or the assay kit A (Comparative Example 1) and the prepared DUPAN-2 antigen solution. The DUPAN-2 antigen solution (13 μL) and the first reagent (137 μL) were added to the reaction cell at a reaction temperature of 37°C, uniformly stirred for about 1 second using the scraper stirring mechanism of the automatic analyzer 3500, and then kept for 5 minutes. Then, while keeping at 37°C, the second reagent (50 μL) was added to the mixed solution of the DUPAN-2 antigen solution and the first reagent in the reaction cell, and uniformly stirred for about 1 second using the scraper stirring mechanism of the automatic analyzer 3500, to prepare a reaction solution (DUPAN-2 antigen concentration: 0 U / mL, 1800 U / mL, and 3600 U / mL). In addition, the above-mentioned sample diluent was used to replace the prepared DUPAN-2 antigen solution to prepare a reaction solution with a DUPAN-2 antigen concentration of 0 U / mL. Then, the difference (ΔAbs) between the absorbance of the reaction solution at 570 nm after 30 seconds and the absorbance of the reaction solution at 570 nm after 300 seconds was measured, and the value of ΔAbs amplified 10,000 times was used as the measured value. The average value of the measured values when the reaction solutions with DUPAN-2 antigen concentrations of 0 U / mL, 1800 U / mL and 3600 U / mL were measured three times was calculated. The results are shown in Table 1.
[0234] Table 1
[0235]
[0236] The higher the measured value of the reaction solution with DUPAN-2 antigen concentration of 1800U / mL and 3600U / mL relative to the measured value of the reaction solution with DUPAN-2 antigen concentration of 0U / mL, the higher the sensitivity of the measurement can be evaluated. As shown in Table 1, compared with the case of using the measurement kit A (Comparative Example 1), the measured values of the reaction solution with DUPAN-2 antigen concentration of 1800U / mL and 3600U / mL relative to the measured value of the reaction solution with DUPAN-2 antigen concentration of 0U / mL are higher when the measurement kits 1 to 3 (Examples 1 to 3) are used. Therefore, it can be seen that if the measurement kit in which the average particle size of the latex particles used is 200nm, 300nm or 400nm is used, the sensitivity of the measurement of the DUPAN-2 antigen is improved compared with the measurement kit in which the average particle size of the latex particles used is 100nm.
[0237] [Experimental Example 2] Evaluation of the relationship between stirring method and measurement sensitivity
[0238] Prepare assay kits 4 to 6 (Examples 4 to 6) having the same composition as assay kits 1 to 3, and assay kit B (Comparative Example 2) having the same composition as assay kit A. Use an automatic analyzer LABOSPECT 006 (manufactured by Hitachi High-Tech Co., Ltd.) instead of the automatic analyzer 3500 with a scraper stirring mechanism of Experimental Example 1, and use the ultrasonic stirring mechanism possessed by the above-mentioned automatic analyzer LABOSPECT 006 to uniformly stir the mixed solution of various solutions and reagents for about 1 second. In addition, the DUPAN-2 antigen was measured using assay kits 4 to 6 and assay kit B in the same manner as in Experimental Example 1. Calculate the average value of the measured values when the reaction solutions with DUPAN-2 antigen concentrations of 0 U / mL, 1800 U / mL and 3600 U / mL were measured three times. The results are shown in Table 2.
[0239] Table 2
[0240]
[0241] Compared with the case of using the automatic analyzer 3500 (scraper stirring), when the automatic analyzer LABOSPECT 006 (ultrasonic stirring) is used, the measured values of the reaction solutions with DUPAN-2 antigen concentrations of 1800U / mL and 3600U / mL are higher relative to the measured values of the reaction solution with DUPAN-2 antigen concentration of 0U / mL. In addition, regarding the measured values when measuring the reaction solution with DUPAN-2 antigen concentration of 0U / mL, since there is no DUPAN-2 antigen as the component to be measured, it is preferably close to 0. As can be seen from Table 2, compared with the case of using the automatic analyzer 3500 (scraper stirring), when the automatic analyzer LABOSPECT 006 (ultrasonic stirring) is used, the measured values are closer to 0 than the measured values when measuring the reaction solution with DUPAN-2 antigen concentration of 0U / mL. Therefore, it can be seen that the mixed solution of various solutions and reagents is uniformly stirred using an ultrasonic stirring mechanism, that is, the sensitivity of the measurement is improved by treating the sample with ultrasonic waves.
[0242] [Experimental Example 3] Evaluation of the relationship between metal ions and measurement sensitivity
[0243] <Preparation of Assay Kit>
[0244] Assay kits 7 to 9 (Examples 7 to 9) having the same composition as those of assay kits 1 to 3 (Examples 1 to 3) were prepared except that magnesium sulfate (150 mmol / L) was contained instead of sodium chloride (150 mmol / L) in the first reagent of assay kits 1 to 3 (Examples 1 to 3).
[0245] A measuring kit C (Comparative Example 3) having the same composition as that of Comparative Example 1 was prepared except that magnesium sulfate (150 mmol / L) was contained instead of sodium chloride (150 mmol / L) contained in the first reagent of the measuring kit A of Comparative Example 1.
[0246] <Evaluation of the Relationship between Metal Ions and Measurement Sensitivity>
[0247] The DUPAN-2 antigen was measured by the same method as in Experimental Example 1 except that the assay kits 7 to 9 (Examples 7 to 9) were used instead of the assay kits 1 to 3 (Examples 1 to 3), and the assay kit C (Comparative Example 3) was used instead of the assay kit A (Comparative Example 1). The average value of the measured values when the reaction solutions having DUPAN-2 antigen concentrations of 0 U / mL, 1800 U / mL, and 3600 U / mL were measured three times was calculated. The results are shown in Table 3.
[0248] Table 3
[0249]
[0250] As shown in Tables 1 and 3, when using assay kits 7 to 9, the measured values of the reaction solutions with DUPAN-2 antigen concentrations of 1800 U / mL and 3600 U / mL were higher than the measured values of the reaction solutions with DUPAN-2 antigen concentrations of 0 U / mL. Therefore, it can be seen that when using an assay kit containing a divalent or higher metal ion, the sensitivity of the measurement is improved compared to when using an assay kit containing a monovalent metal ion.
Claims
1. A latex agglutination immunoassay method for sialyl Lewis antigen in a sample, comprising reacting the sialyl Lewis antigen in the sample with latex particles bound with an antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen in an aqueous medium, wherein: The average particle size of the latex particles is 200nm to 400nm.
2. The method according to claim 1, comprising the step of treating the sample with ultrasound.
3. A latex agglutination immunoassay method for sialyl Lewis antigen in a sample, comprising: (1) a step of mixing a sample containing a sialyl Lewis antigen with an aqueous medium; and (2) a step of reacting the sialyl Lewis antigen in the sample with latex particles to which an antibody or an antigen-binding fragment thereof that recognizes the sialyl Lewis antigen is bound, in the solution obtained in step (1); in, The average particle size of the latex particles in step (2) is 200 nm to 400 nm.
4. The method according to claim 3, wherein: After the step (1) and / or after the step (2), the method further includes treating the sample with ultrasonic waves.
5. The method according to claim 3 or 4, wherein: The step (1) and / or the step (2) is performed in the presence of metal ions.
6. The method according to claim 5, wherein: The metal ions are divalent or higher valent metal ions.
7. The method according to any one of claims 1 to 4, wherein: The binding of the antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen to the latex particles is chemical binding.
8. The method according to any one of claims 1 to 4, wherein: The sialyl Lewis antigen is DUPAN-2 antigen.
9. A reagent for latex agglutination immunoassay of sialyl Lewis antigen in a sample, comprising latex particles to which an antibody recognizing sialyl Lewis antigen or an antigen-binding fragment thereof is bound, wherein the latex particles have an average particle size of 200 nm to 400 nm.
10. The reagent according to claim 9, wherein The latex agglutination immunoassay comprises the step of treating the sample with ultrasonic waves. The reagent according to claim 9 , comprising instructions for treating the sample with ultrasonic waves.
12. The reagent according to claim 9, which is used in an analysis device equipped with an ultrasonic processing function. 13 . The reagent according to claim 9 , comprising a metal ion.
14. The reagent according to claim 13, wherein The metal ions are divalent or higher valent metal ions.
15. The reagent according to any one of claims 9 to 12, wherein The binding of the antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen to the latex particles is chemical binding.
16. The reagent according to any one of claims 9 to 12, wherein The sialyl Lewis antigen is DUPAN-2 antigen.
17. A kit for latex agglutination immunoassay of sialyl Lewis antigen in a sample, comprising: A first reagent comprising an aqueous medium, and a second reagent comprising latex particles to which an antibody recognizing a sialyl Lewis antigen or an antigen-binding fragment thereof is bound; in, The average particle size of the latex particles is 200nm to 400nm.
18. The kit according to claim 17, wherein The latex agglutination immunoassay comprises the step of treating the sample with ultrasonic waves. The kit according to claim 17 , comprising instructions for treating the sample with ultrasound.
20. The kit according to claim 17, which is used in an analysis device equipped with an ultrasonic processing function.
21. The kit according to any one of claims 17 to 20, wherein The first reagent and / or the second reagent contains metal ions.
22. The kit according to claim 21, wherein The metal ions are divalent or higher valent metal ions.
23. The kit according to any one of claims 17 to 20, wherein The binding of the antibody or antigen-binding fragment thereof that recognizes the sialyl Lewis antigen to the latex particles is chemical binding.
24. The kit according to any one of claims 17 to 20, wherein The sialyl Lewis antigen is DUPAN-2 antigen.
Citation Information
Cited By
Mycoplasma pneumoniae antibody detection kit based on immunoturbidimetry
CN122307101A
